OMNIlife science is evaluating the OMNIBotics® Active Spacer robotic tissue balancing device at three U.S. clinical sites.
The Active Spacer entered clinical use in Australia at the end of 1Q17, and received FDA 510(k) clearance at the end of 3Q17. Combined with the alignment and cutting guidance of OMNIBotics, the spacer is intended to help manage soft tissue stability in the knee. This responds to patient commentary on a lack of full satisfaction following a knee replacement procedure.
OMNIlife science is evaluating the OMNIBotics® Active Spacer robotic tissue balancing device at three U.S. clinical sites. The Active Spacer entered clinical use in Australia at the end of 1Q17, and received FDA 510(k) clearance at the end of 3Q17. Combined with the alignment and cutting guidance of OMNIBotics, the spacer is intended to help...
OMNIlife science is evaluating the OMNIBotics® Active Spacer robotic tissue balancing device at three U.S. clinical sites.
The Active Spacer entered clinical use in Australia at the end of 1Q17, and received FDA 510(k) clearance at the end of 3Q17. Combined with the alignment and cutting guidance of OMNIBotics, the spacer is intended to help manage soft tissue stability in the knee. This responds to patient commentary on a lack of full satisfaction following a knee replacement procedure.
Copy to clipboard 
